Advertisement
Advertisement

ONCY

ONCY logo

Oncolytics Biotech, Inc. Common Shares

0.99
USD
Sponsored
-0.02
-1.98%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

1.01

+0.02
+1.62%

ONCY Earnings Reports

Positive Surprise Ratio

ONCY beat 22 of 39 last estimates.

56%

Next Report

Date of Next Report
Mar 05, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.07
Implied change from Q3 25 (Revenue/ EPS)
--
/
-50.00%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-30.00%

Oncolytics Biotech, Inc. Common Shares earnings per share and revenue

On Nov 12, 2025, ONCY reported earnings of -0.14 USD per share (EPS) for Q3 25, missing the estimate of -0.09 USD, resulting in a -43.53% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.85% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 4 analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an decrease of -50.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q3 2025, Oncolytics Biotech, Inc. Common Shares reported EPS of -$0.14, missing estimates by -43.53%, and revenue of $0.00, 0% as expectations.
The stock price moved down -4.85%, changed from $1.14 before the earnings release to $1.08 the day after.
The next earning report is scheduled for Mar 05, 2026.
Based on 4 analysts, Oncolytics Biotech, Inc. Common Shares is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement